AtriCure (ATRC) Tops Q1 EPS by 8c ; Offers Guidance

AtriCure (NASDAQ: ATRC) reported Q1 EPS of ($0.14), $0.08 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $123.6 million versus the consensus estimate of $123.08 million.

GUIDANCE:

AtriCure sees FY2025 EPS of ($0.50)-($0.55), versus the consensus of ($0.58). AtriCure sees FY2025 revenue of $517-527 million, versus the consensus of $522.8 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• Dick's Sporting Goods (DKS) Misses Q2 EPS by 25c, Offers Guidance
• Tuya Inc. (TUYA) Reports In-Line Q2 EPS
• Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'